NO20016121L - Preparater og fremgangsmåter for å öke kolesterolutströmning og heve HDL ved anvendelse av ATP-bindingskassett-transportörprotein ABC1 - Google Patents
Preparater og fremgangsmåter for å öke kolesterolutströmning og heve HDL ved anvendelse av ATP-bindingskassett-transportörprotein ABC1Info
- Publication number
- NO20016121L NO20016121L NO20016121A NO20016121A NO20016121L NO 20016121 L NO20016121 L NO 20016121L NO 20016121 A NO20016121 A NO 20016121A NO 20016121 A NO20016121 A NO 20016121A NO 20016121 L NO20016121 L NO 20016121L
- Authority
- NO
- Norway
- Prior art keywords
- methods
- abc
- relates
- polypeptides
- well
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
Abstract
Foreliggende oppfinnelse angår nye ABC 1-polypeptider og nukleinsyremolekyler som koder for det samme. Oppfinnelsen angår også rekombinante vektorer, vertsceller og preparater som omfatter ABCl-polynukleotider, så vel som fremgangsmåter for å frem-stille ABC 1-polypeptider. Oppfinnelsen angår også antistoffer som binder spesifikt til ABC 1-polypeptider. I tillegg angår oppfinnelsen fremgangsmåter for å øke kolesterolut-strømning så vel som fremgangsmåter for å øke ABC 1-ekspresjon og aktivitet. Foreliggende oppfinnelse angår videre fremgangsmåter for å identifisere forbindelser som modulerer ekspresjonen av ABC1 samt fremgangsmåter for å påvise det komparative nivå-et av ABC 1-polypeptider og polynukleotider i et pattedyr. Foreliggende oppfinnelse tilveiebringer også kit og preparater som er egnet til å screene forbindelser for å bestemme den ABCl-ekspresjonsmodulerende aktiviteten til forbindelsen, så vel som kit og preparater som er egnet til å bestemme hvorvidt en forbindelse modulerer ABC1-avhengig kolesterolutstrømning.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14026499P | 1999-06-18 | 1999-06-18 | |
| US15387299P | 1999-09-14 | 1999-09-14 | |
| US16657399P | 1999-11-19 | 1999-11-19 | |
| PCT/US2000/016591 WO2000078971A2 (en) | 1999-06-18 | 2000-06-16 | Atp binding cassette transporter protein abc1 popypeptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20016121D0 NO20016121D0 (no) | 2001-12-14 |
| NO20016121L true NO20016121L (no) | 2002-02-12 |
Family
ID=27385472
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20016114A NO20016114L (no) | 1999-06-18 | 2001-12-14 | Preparater og fremgangsmåter for å öke kolesterolutströmming og heve HDL ved anvendelse av ATP-bindingskassett-transportörprotein ABC1 |
| NO20016121A NO20016121L (no) | 1999-06-18 | 2001-12-14 | Preparater og fremgangsmåter for å öke kolesterolutströmning og heve HDL ved anvendelse av ATP-bindingskassett-transportörprotein ABC1 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20016114A NO20016114L (no) | 1999-06-18 | 2001-12-14 | Preparater og fremgangsmåter for å öke kolesterolutströmming og heve HDL ved anvendelse av ATP-bindingskassett-transportörprotein ABC1 |
Country Status (19)
| Country | Link |
|---|---|
| EP (2) | EP1218515B1 (no) |
| JP (4) | JP2003508031A (no) |
| KR (2) | KR20020012612A (no) |
| CN (2) | CN1379817A (no) |
| AR (2) | AR024576A1 (no) |
| AT (1) | ATE422545T1 (no) |
| AU (3) | AU5743400A (no) |
| BR (2) | BR0011753A (no) |
| CA (2) | CA2375781A1 (no) |
| DE (1) | DE60041545D1 (no) |
| HK (2) | HK1046427A1 (no) |
| IL (2) | IL147021A0 (no) |
| MX (2) | MXPA01013175A (no) |
| NO (2) | NO20016114L (no) |
| NZ (3) | NZ529785A (no) |
| SG (2) | SG121853A1 (no) |
| TR (2) | TR200200441T2 (no) |
| TW (2) | TWI304737B (no) |
| WO (2) | WO2000078971A2 (no) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1854880A1 (en) * | 1999-03-15 | 2007-11-14 | University of British Columbia | Methods and reagents for modulating cholesterol levels |
| CA2367955C (en) | 1999-03-15 | 2009-05-19 | University Of British Columbia | Abc1 polypeptide and methods and reagents for modulating cholesterol levels |
| WO2001003705A1 (en) * | 1999-07-08 | 2001-01-18 | Tularik Inc. | Compositions and methods for raising hdl cholesterol levels |
| EP1239848A2 (en) * | 1999-09-01 | 2002-09-18 | University of British Columbia | Compositions and methods for modulating hdl cholesterol and triglyceride levels |
| US6555323B2 (en) * | 2000-02-08 | 2003-04-29 | Pfizer Inc. | Assay for ABCA1 |
| BR0110541A (pt) | 2000-05-02 | 2003-04-01 | Aventis Pharma Sa | ácido nucleico isolado, vetor recombinante, célula hospedeira, mamìfero transgênico não-humano, método para triar uma substância ou uma molécula, kit para triar, in vitro, uma molécula ou substância candidato, método para triar, in vivo, uma substância ou molécula, kit ou pacote para triar, in vivo, pelo menos uma molécula ou substância candidato, substância que modifica a transcrição de um polinucleotìdeo de interesse, composição farmacêutica, método e kit para detectar um enfraquecimento da transcrição do gene abc1 em um indivìduo, e, kit ou pacote para triar uma molécula ou substância candidato |
| EP1203588A1 (en) * | 2000-11-06 | 2002-05-08 | Bayer Ag | Sterol-independent regulation of ABC1 promoter via oncostatinM |
| US7033790B2 (en) | 2001-04-03 | 2006-04-25 | Curagen Corporation | Proteins and nucleic acids encoding same |
| WO2003004692A2 (en) * | 2001-07-03 | 2003-01-16 | Xenon Genetics, Inc. | Screening processes for agents modulating cholesterol levels |
| WO2003033023A1 (fr) * | 2001-10-12 | 2003-04-24 | Grelan Pharmaceutical Co., Ltd. | Medicaments ameliorant l'hypocholesterolemie hdl |
| US6924311B2 (en) | 2001-10-17 | 2005-08-02 | X-Ceptor Therapeutics, Inc. | Methods for affecting various diseases utilizing LXR compounds |
| ES2367539T3 (es) | 2001-12-21 | 2011-11-04 | X-Ceptor Therapeutics, Inc. | Moduladores heterocíclicos de receptores nucleares. |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| AU2002351412B2 (en) | 2001-12-21 | 2010-05-20 | Exelixis Patent Company Llc | Modulators of LXR |
| WO2004058717A1 (en) | 2002-12-20 | 2004-07-15 | X-Ceptor Therapeutics, Inc. | Isoquinolinone derivatives and their use as therapeutic agents |
| US8466143B2 (en) | 2003-07-23 | 2013-06-18 | Exelixis, Inc. | Azepine derivatives as pharmaceutical agents |
| WO2005116057A1 (en) * | 2004-05-27 | 2005-12-08 | Baker Medical Research Institute | Monoclonal antibody against abca1 |
| MX363423B (es) | 2005-05-18 | 2019-03-22 | Ablynx Nv | Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor. |
| MX2007014564A (es) | 2005-05-20 | 2008-02-07 | Ablynx Nv | Anticuerpos de vhh de dominio unico contra el factor de von willebrand. |
| CA2613522A1 (en) | 2005-06-27 | 2007-01-04 | Exelixis, Inc. | Imidazole based lxr modulators |
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| JP5227803B2 (ja) | 2006-11-24 | 2013-07-03 | ハイクス ラボラトリーズ合同会社 | スピロキノン化合物及び医薬組成物 |
| EP2102244A2 (en) | 2006-12-19 | 2009-09-23 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders |
| US20100062004A1 (en) | 2006-12-19 | 2010-03-11 | Ablynx N.V. | Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders |
| CA2706425A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
| JP2011525476A (ja) | 2008-03-05 | 2011-09-22 | アブリンクス エン．ヴェー． | 新規の抗原結合二量体複合体、その製造方法及び使用 |
| CA2720763A1 (en) | 2008-04-07 | 2009-10-15 | Ablynx Nv | Amino acid sequences directed against the notch pathways and uses thereof |
| EP2403873A1 (en) | 2009-03-05 | 2012-01-11 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
| US20120053229A1 (en) * | 2009-03-31 | 2012-03-01 | The General Hospital Corporation | Regulation of MIR-33 MicroRNAs in the Treatment of Cholesterol-Related Disorders |
| AU2010233658B2 (en) | 2009-04-10 | 2013-11-28 | Ablynx Nv | Improved amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of IL-6R related diseases and disorders |
| SI2435410T1 (sl) | 2009-05-28 | 2017-06-30 | Bristol-Myers Squibb Company | Lxr modulatorji |
| WO2011045079A1 (en) | 2009-10-15 | 2011-04-21 | Intercell Ag | Hepatitis b virus specific human antibodies |
| AR083784A1 (es) | 2010-11-08 | 2013-03-20 | Novartis Ag | Polipeptidos de enlace de los receptores de quimiocina |
| TW201242953A (en) | 2011-03-25 | 2012-11-01 | Bristol Myers Squibb Co | Imidazole prodrug LXR modulators |
| EP2723772A1 (en) | 2011-06-23 | 2014-04-30 | Ablynx N.V. | Immunoglobulin single variable domains directed against ige |
| US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
| KR20150023729A (ko) | 2012-06-14 | 2015-03-05 | 암브룩스, 인코포레이티드 | 핵 수용체 리간드 폴리펩티드에 접합된 항-psma 항체 |
| US9101745B2 (en) * | 2013-03-14 | 2015-08-11 | Sonogene Llc | Sonochemical induction of ABCA1 expression and compositions therefor |
| JP6442475B2 (ja) | 2013-03-15 | 2018-12-19 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｌｘｒ調節因子 |
| WO2014152738A1 (en) | 2013-03-15 | 2014-09-25 | Bristol-Myers Squibb Company | Lxr modulators |
| NL1040254C2 (en) | 2013-05-17 | 2014-11-24 | Ablynx Nv | Stable formulations of immunoglobulin single variable domains and uses thereof. |
| GB201315136D0 (en) * | 2013-08-23 | 2013-10-09 | Univ Glasgow | Cholesterol modulation |
| NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
| TN2018000180A1 (en) | 2015-11-27 | 2019-10-04 | Ablynx Nv | Polypeptides inhibiting cd40l |
| US11098113B2 (en) | 2016-09-15 | 2021-08-24 | Vib Vzw | Immunoglobulin single variable domains directed against macrophage migration inhibitory factor |
| BR112019010061A2 (pt) | 2016-11-16 | 2019-08-13 | Ablynx Nv | polipeptídeos de recrutamento de células t capazes de se ligarem ao cd123 e tcr alfa/beta |
| CA3064318A1 (en) | 2017-06-02 | 2018-12-06 | Merck Patent Gmbh | Polypeptides binding adamts5, mmp13 and aggrecan |
| SG10202113337YA (en) | 2017-06-02 | 2021-12-30 | Ablynx Nv | Aggrecan binding immunoglobulins |
| AU2018277343A1 (en) | 2017-06-02 | 2020-01-02 | Ablynx N.V. | Adamts binding immunoglobulins |
| EP3630178A1 (en) | 2017-06-02 | 2020-04-08 | Merck Patent GmbH | Mmp13 binding immunoglobulins |
| CN115433733A (zh) | 2021-06-04 | 2022-12-06 | 生物岛实验室 | 环状RNA Circ-ACE2翻译的多肽及其应用 |
| CN114369162B (zh) | 2021-12-28 | 2023-05-30 | 合肥天港免疫药物有限公司 | 抗体及其应用 |
| WO2024023271A1 (en) | 2022-07-27 | 2024-02-01 | Ablynx Nv | Polypeptides binding to a specific epitope of the neonatal fc receptor |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0110541A (pt) * | 2000-05-02 | 2003-04-01 | Aventis Pharma Sa | ácido nucleico isolado, vetor recombinante, célula hospedeira, mamìfero transgênico não-humano, método para triar uma substância ou uma molécula, kit para triar, in vitro, uma molécula ou substância candidato, método para triar, in vivo, uma substância ou molécula, kit ou pacote para triar, in vivo, pelo menos uma molécula ou substância candidato, substância que modifica a transcrição de um polinucleotìdeo de interesse, composição farmacêutica, método e kit para detectar um enfraquecimento da transcrição do gene abc1 em um indivìduo, e, kit ou pacote para triar uma molécula ou substância candidato |
-
2000
- 2000-06-16 KR KR1020017016286A patent/KR20020012612A/ko not_active Application Discontinuation
- 2000-06-16 AR ARP000103013A patent/AR024576A1/es unknown
- 2000-06-16 MX MXPA01013175A patent/MXPA01013175A/es active IP Right Grant
- 2000-06-16 NZ NZ529785A patent/NZ529785A/en unknown
- 2000-06-16 EP EP00942914A patent/EP1218515B1/en not_active Expired - Lifetime
- 2000-06-16 IL IL14702100A patent/IL147021A0/xx unknown
- 2000-06-16 CA CA002375781A patent/CA2375781A1/en not_active Abandoned
- 2000-06-16 EP EP00942867A patent/EP1190065A2/en not_active Withdrawn
- 2000-06-16 AT AT00942914T patent/ATE422545T1/de not_active IP Right Cessation
- 2000-06-16 WO PCT/US2000/016591 patent/WO2000078971A2/en not_active Application Discontinuation
- 2000-06-16 BR BR0011753-6A patent/BR0011753A/pt not_active Application Discontinuation
- 2000-06-16 JP JP2001515880A patent/JP2003508031A/ja active Pending
- 2000-06-16 KR KR10-2001-7016284A patent/KR100476519B1/ko not_active IP Right Cessation
- 2000-06-16 CA CA002375787A patent/CA2375787C/en not_active Expired - Fee Related
- 2000-06-16 TR TR2002/00441T patent/TR200200441T2/xx unknown
- 2000-06-16 WO PCT/US2000/016765 patent/WO2000078972A2/en not_active Application Discontinuation
- 2000-06-16 SG SG200307656A patent/SG121853A1/en unknown
- 2000-06-16 DE DE60041545T patent/DE60041545D1/de not_active Expired - Fee Related
- 2000-06-16 AU AU57434/00A patent/AU5743400A/en not_active Abandoned
- 2000-06-16 NZ NZ516061A patent/NZ516061A/en unknown
- 2000-06-16 JP JP2001515881A patent/JP2003506097A/ja active Pending
- 2000-06-16 TR TR2002/00440T patent/TR200200440T2/xx unknown
- 2000-06-16 AU AU57467/00A patent/AU777461B2/en not_active Ceased
- 2000-06-16 CN CN00809163A patent/CN1379817A/zh active Pending
- 2000-06-16 BR BR0011696-3A patent/BR0011696A/pt not_active IP Right Cessation
- 2000-06-16 AR ARP000103012A patent/AR024391A1/es unknown
- 2000-06-16 IL IL14702200A patent/IL147022A0/xx unknown
- 2000-06-16 MX MXPA01013174A patent/MXPA01013174A/es unknown
- 2000-06-16 CN CNB008091641A patent/CN100513570C/zh not_active Expired - Fee Related
- 2000-06-16 NZ NZ531401A patent/NZ531401A/en unknown
- 2000-06-16 SG SG200307655A patent/SG121852A1/en unknown
- 2000-08-25 TW TW095113205A patent/TWI304737B/zh active
- 2000-08-25 TW TW089111924A patent/TWI259205B/zh not_active IP Right Cessation
-
2001
- 2001-12-14 NO NO20016114A patent/NO20016114L/no unknown
- 2001-12-14 NO NO20016121A patent/NO20016121L/no not_active Application Discontinuation
-
2002
- 2002-09-26 HK HK02107131.3A patent/HK1046427A1/zh unknown
- 2002-11-13 HK HK02108234.7A patent/HK1046708A1/zh unknown
-
2004
- 2004-11-04 JP JP2004320358A patent/JP4277956B2/ja not_active Expired - Fee Related
-
2005
- 2005-01-14 AU AU2005200171A patent/AU2005200171A1/en not_active Abandoned
- 2005-10-26 JP JP2005311515A patent/JP2006137750A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20016121L (no) | Preparater og fremgangsmåter for å öke kolesterolutströmning og heve HDL ved anvendelse av ATP-bindingskassett-transportörprotein ABC1 | |
| DK1012274T3 (da) | Dödsdomæneholdig receptor-4 (DR4: dödsreceptor 4), medlem af TNF-receptorsuperfamilien og som binder til TRAIL (Apo-2L) | |
| DE69836956D1 (de) | Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält | |
| DK0981618T3 (da) | Anti-Apo-2-antistof | |
| DK1032660T3 (da) | Fremgangsmåde til identivicering af bindingsstedsdominans som bevarer evnen til at binde til en epitop | |
| CA2341636A1 (en) | Fusion proteins, dna molecules, vectors, and host cells useful for measuring protease activity | |
| Sebastiano et al. | A new deuterated alkylating agent for quantitative proteomics | |
| CA2063822A1 (en) | Method of transcriptionally modulating gene expression and of discovering chemicals capable of functioning as gene expression modulators | |
| DE60234131D1 (de) | Neue fusionsproteine und molekulare bindungsassays | |
| CA2148252A1 (en) | Interaction trap system for isolating novel proteins | |
| DK0576623T4 (da) | Bindingsdomæner i Notch-proteiner | |
| DK1005488T4 (da) | Receptor som binder TRAIL | |
| EP1454992B1 (en) | Anaplastic lymphoma kinase assay, reagents and compositions thereof | |
| EP0999271A3 (en) | Retinoid receptor compositions and methods | |
| WO2005069900B1 (en) | Npc1l1 (npc3) and methods of identifying ligands thereof | |
| WO1999043808A8 (en) | Human c-maf compositions and methods of use thereof | |
| NO962084L (no) | DNA sekvens som koder for en BMP reseptor | |
| DK1009817T3 (da) | RTD-receptor | |
| WO1999047686A3 (en) | Human mekk proteins, corresponding nucleic acid molecules, and uses therefor | |
| Trimmer et al. | 36 Phosphorylation of voltage-gated ion channels | |
| ATE308615T1 (de) | T-bet zusammensetzungen und deren vervendungsmethoden | |
| WO2002087606A3 (en) | Modulators of the hypocretin system and methods of screening therefor | |
| NO983984L (no) | Disintegrin-metalloprotease samt anvendelse derav | |
| EA200300420A1 (ru) | Выделенная молекула нуклеиновой кислоты, выделенный полипептид и способ его получения, способ обнаружения их присутствия в образце (варианты), клетка-хозяин (варианты), антитело, набор (варианты), способ модулирования активности полипептида, способ идентификации (варианты) и применение соединения, способ выявления субъекта (варианты) и способ лечения субъекта с нарушением, связанным с калиевыми каналами (варианты) | |
| WO2002004601A3 (en) | Mammalian mdm2 binding proteins and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |